JNNP:慢性卒中后失语症患者强制诱导或多模态失语症治疗与常规治疗的对比试验结果

2022-05-20 网络 网络

失语症是一种后天习得的语言障碍,影响以语言为基础的交流的各个方面:理解言语、阅读、写作和口语。在大约20%的中风幸存者中,失语症持续到慢性期, 对心理健康和生活质量有显著的负面影响。中风后第一年,失语

失语症是一种后天习得的语言障碍,影响以语言为基础的交流的各个方面:理解言语、阅读、写作和口语。在大约20%的中风幸存者中,失语症持续到慢性期, 对心理健康和生活质量有显著的负面影响。中风后第一年,失语症占中风相关医疗费用的8.5%。 2016年《Cochrane中风后失语症言语和语言治疗回顾》显示,在功能性沟通干预(SMD 0.28,95%可信区间0.06至0.49,p=0.01)后,当治疗强度足够(每周5-10小时)时,治疗效果在统计学上显著,但在6个月的随访中没有。该综述缺乏比较治疗效果的证据, 限制了有效治疗的方法。中风和失语症严重程度是可能的调节变量。有必要进行适当的试验,比较慢性期不同失语症治疗的有效性。

强制性诱导失语症治疗 (CIAT Plus)和多模态失语症治疗加(M-MAT)是在2-4名参与者的小组环境中进行的密集、高剂量干预,旨在改善言语交流。它们涉及不同的治疗策略:CIAT加偏好言语产生和言语治疗师提示;M-MAT包括多模态任务和提示(绘画、手势和写作)。假设CIAT Plus和M-MAT依赖于不同的潜在神经恢复机制,并且根据失语症的严重程度可能有不同的效果。对CIAT Plus和M-MAT试验的系统性审查显示中-高效应大小,但研究受到小样本量(n<15)、比较组不足以及招募和检测偏差的限制。为基于严重程度的失语症患者和其他亚组失语症患者确定最有效的干预措施可能会改善患者预后,降低医疗成本。

强制性诱导或多模态个性化失语症康复(COMPARE)多中心随机对照试验的目的是评估2周强化剂量(30小时)治疗(CIAT Plus或M-MAT)与低剂量常规社区护理(常规护理,UC)治疗中风后慢性失语症的比较有效性。本文的目的是根据治疗前失语症的严重程度调查潜在的差异影响。我们的主要假设是,与UC相比,CIAT Plus和M-MAT在干预后会立即导致失语症严重程度显著降低,M-MAT优于轻度和重度失语症,CIAT Plus优于中度失语症。进一步假设,与UC相比,两种治疗方法都能改善单词检索、功能性交流、多模式交流和生活质量。第三个目标(此处未报告)是报告这些干预措施的潜在增量成本效益。本文发表在《神经病学,神经外科学和精神病学杂志》上()。

进行了一项三组、多中心、平行组、开放标签、盲法终点、三期、随机对照试验。根据西方失语症组修正失语症商(WAB-R-AQ)对符合条件的参与者进行基线失语症分层。由三名参与者组成的小组被随机分配(1:1:1)30小时的CIAT Plus或M-MAT或常规护理(UC)。主要结果是在意向治疗人群中分析的失语症严重程度(WAB-R-AQ)从基线检查到治疗完成的变化。次要结果包括单词检索、连接语音、功能性沟通、多模式沟通、生活质量和成本。治疗是面对面进行的,由三名参与者组成,要求治疗组成员在同一地理位置。一旦纳入试验,参与者根据失语症的严重程度被分配到治疗组(WAB-R-AQ轻度:93.7-62.6;中度:62.5-31.3;重度:≤31.3)。CIAT Plus和M-MAT治疗疗程每天3小时,每周5天,持续2周(30小时)。每1小时的休息时间间隔为15-30分钟。规定每天15分钟的家庭实践沟通任务,第二天检查完成情况,并记录在比较研究电子数据采集(REDCap)数据库中。CIAT Plus和M-MAT由合格且经过研究培训的语言病理学家在社区环境中提供。

                                                                                                     研究流程

CIAT Plus和M-MAT涉及六种不同的结构化、协议化的交流活动,包括请求项目、澄清请求、从记忆中回忆项目和命名项目。根据参与者预处理图片命名的准确性,在治疗中使用80张彩色图片卡(48个名词;32个动词)的规定集(简单、中等、硬)。在CIAT Plus中,参与者不允许使用纸笔或增强型交流设备,将所有活动都集中在口语交流上。在纳入研究前的筛查中收集了人口统计学、医学/健康、情绪、言语和语言特征。所有主要和次要结果均在干预期开始前2周(基线)、干预结束后7天(干预后即刻)和12周随访时间点后7天内收集。

 基线、干预后和随访时的平均结果指标

分析了201名参与者(CIAT Plus 70人,M-MAT 70人,UC 61人)。所有参与者的平均年龄为63.6岁(IQR 18.7),范围为18-92岁,147名(68%)为男性。在基线检查时,154名参与者(71.3%)患有轻度失语,56名参与者(25.9%)患有中度失语,6名参与者(2.8%)患有重度失语。受试者中风后平均年龄为2.55岁(IQR为3.75岁)(范围为6.4个月至28岁)。尽管UC参与者更独立(mRS分数较低)、更年轻、没有严重失语症的参与者、话语和命名分数较高,但干预组在基线检查时基本相似。干预后各组失语症严重程度无显著差异:UC组与CIAT Plus组1.05分(95%CI−0.78至2.88;p=0.36);UC组与M-MAT组1.06分(95%可信区间)−0.78至2.89;p=0.36);CIAT Plus 与 M-MAT组0.004分(95%可信区间)−1.76至1.77;p=1.00)。使用CIAT Plus和M-MAT后,单词检索、功能性交流和与交流相关的生活质量显著改善。在12周的随访中,单词检索的益处得以维持。

该试验比较了慢性卒中后失语症患者的大样本。总体而言,平均而言,与有限社区UC相比,在2周内进行30小时的CIAT Plus或M-MAT并没有显著降低整体失语症的严重程度。然而,基线失语症严重程度可能会影响结果,干预后WAB-R-AQ的差异有利于中度失语症的CIAT Plus,重度失语症的M-MAT,以及随访时轻度失语症的M-MAT。与UC相比,两种治疗均显著改善了单词检索、功能性沟通和沟通相关的生活质量,M-MAT优于沟通相关的生活质量,CIAT Plus优于单词检索。这些都是重要的差异性发现。研究结果是对个性化康复有重要意义。

Rose MLNickels LCopland D, et al Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-28 ms8000001751409308

    好文

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 ms2000000544679768

    谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1689751, encodeId=fc5b1689e510d, content=<a href='/topic/show?id=a7c54431571' target=_blank style='color:#2F92EE;'>#失语#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44315, encryptionId=a7c54431571, topicName=失语)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adcc28855380, createdName=1696533704_45270463, createdTime=Tue Oct 04 10:49:16 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942951, encodeId=cd91194295181, content=<a href='/topic/show?id=3e40443166e' target=_blank style='color:#2F92EE;'>#失语症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44316, encryptionId=3e40443166e, topicName=失语症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Mon Jul 18 18:49:16 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022399, encodeId=9d782022399b5, content=<a href='/topic/show?id=907243308f5' target=_blank style='color:#2F92EE;'>#多模态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43308, encryptionId=907243308f5, topicName=多模态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat Jan 14 01:49:16 CST 2023, time=2023-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671475, encodeId=60df16e1475e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Tue Oct 25 00:49:16 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706274, encodeId=9e501e06274dc, content=<a href='/topic/show?id=de5a486e6b0' target=_blank style='color:#2F92EE;'>#常规治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48676, encryptionId=de5a486e6b0, topicName=常规治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=036131187289, createdName=晓辰, createdTime=Fri Jun 24 20:49:16 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222982, encodeId=5f3e12229820f, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62395728911, createdName=ms8000001751409308, createdTime=Sat May 28 13:02:34 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221179, encodeId=e4fb12211e918, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210905/47d873f313bc47fe9d5d7a69b86d877f/545be3203f2745cab07fbf19b980c439.jpg, createdBy=bea65467125, createdName=ms2000000544679768, createdTime=Fri May 20 14:37:33 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221157, encodeId=75e4122115e8e, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri May 20 12:43:40 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 yangchou

    好文章,谢谢分享。

    0

相关资讯

STROKE:有氧锻炼有助改善慢性卒中患者康复

  西印度群岛学者的一项研究表明,在慢性卒中患者中,有氧锻炼可改善躯体健康生活质量及耐力。论文于2013年3月7日在线发表于《卒中》(Stroke)。   此项单盲、随机独照试验共纳入128例卒中存活者。干预组受试者(64例)接受为期12周的每周3次30分钟有氧锻炼(步行)。利用SF-36生活量表、巴氏量表、6分钟步行距离和肌力指数评估健康相关性生活质量、功能状态、耐力和下肢肌力。   结果显

拓展阅读

JAMA Neurol:慢性卒中患者步行康复的最佳强度和持续时间

在慢性中风患者中,剧烈的步行锻炼只需要4周的训练就可以显著提高步行能力,但至少需要12周的时间才能最大限度地提高步行能力。

STROKE:有氧锻炼有助改善慢性卒中患者康复

  西印度群岛学者的一项研究表明,在慢性卒中患者中,有氧锻炼可改善躯体健康生活质量及耐力。论文于2013年3月7日在线发表于《卒中》(Stroke)。   此项单盲、随机独照试验共纳入128例卒中存活者。干预组受试者(64例)接受为期12周的每周3次30分钟有氧锻炼(步行)。利用SF-36生活量表、巴氏量表、6分钟步行距离和肌力指数评估健康相关性生活质量、功能状态、耐力和下肢肌力。   结果显